Company news
Ono Pharmaceutical Co., Ltd. (TSE:4528) news
Ono Pharmaceutical Co., Ltd. news releases on 6ix. Latest, Sep 16, 2026: Ono Pharmaceutical : Received Manufacturing and Marketing Approval in Japan…
Press releases & updates
Ono Pharmaceutical : Received Manufacturing and Marketing Approval in Japan for XCOPRI® Tablets for the Treatment of Patients with Partial-onset Seizures, With or Without Secondary Generalized Seizures
September 16, 2026
KANEKA UBIQUINOL™ MEMENANGI NUTRAINGREDIENTS ASIA INGREDIENT OF THE YEAR: HEALTHSPAN AWARD 2026
September 8, 2026
Ono Pharmaceutical : OPDIVO® Intravenous Infusion Approved in Taiwan for the Treatment of Resectable Non-Small Cell Lung Cancer with Neoadjuvant OPDIVO in Combination with Chemotherapy Followed by Surgery and Adjuvant Single-Agent OPDIVO
August 19, 2026
Ono Pharmaceutical : Continues to be Selected for ESG Investment Indexes Adopted by GPIF
August 17, 2026
Ono Pharmaceutical : OPDIVO® Intravenous Infusion Approved in South Korea for the Treatment of Resectable Non-Small Cell Lung Cancer with Neoadjuvant OPDIVO in Combination with Chemotherapy Followed by Surgery and Adjuvant Single-Agent OPDIVO
August 4, 2026
Consolidated Financial Results for the First Quarter of Fiscal Year Ending March 31, 2027 (IFRS)
July 30, 2026
Ono Pharmaceutical : Notice concerning Completion of Disposal of Treasury Shares as Tenure-based Restricted Stock Compensation and Performance-linked Restricted Stock Compensation
July 9, 2026
Ono Pharmaceutical : Notice of Disposal of Treasury Shares as Tenure-based Restricted Stock Compensation and Performance-linked Restricted Stock Compensation
June 18, 2026
Ono Pharmaceutical : Pharma Submits a Supplemental Application in Japan to Expand the Use of VELEXBRU® Tablets for the Treatment of Central Nervous System Involvement of Malignant Lymphoma in Patients with Inadequate Response to Existing Therapies or in Whom Such Therapies Are Not Appropriate
June 11, 2026
Oncolys BioPharma : Announces Full Marketing Approval in Japan for Telomelysin for the Treatment of Esophageal Cancer
June 8, 2026
Ono Pharmaceutical : Pharma Announces Oral Presentation of New Data from Phase 2 Clinical Study of -4578 (EP4 antagonist) in Certain Gastric Cancers at the ASCO 2026 Annual Meeting
June 1, 2026
Ono Pharma Announces Poster Presentation of New Clinical Data from Phase 2 Study of ONO-2808 (S1P5 Receptor Agonist) in Multiple System Atrophy at the 7th World Parkinson Congress (WPC)
May 27, 2026
Ono Pharmaceutical : Pharma Announces Upcoming Presentations at the ASCO 2026 Annual Meeting
April 21, 2026
Ono Pharmaceutical : Notice concerning Introduction of Long-Term Incentive Stock Plan for Employees of Deciphera, the U.S. Subsidiary
March 4, 2026
Ono Pharmaceutical : Notice Concerning Disposal of Treasury Shares by Third-Party Allotment
March 4, 2026
Sinopia Biosciences Announces Target Discovery Collaboration with Ono Pharmaceutical for Rare Metabolic Disorders
March 3, 2026
Congruence and Ono Pharma Expand Multi-Target Research Partnership with the Addition of Two New Programs
March 2, 2026
Ono Pharmaceutical : Announcement on Changes of the Board of Directors and Corporate Officers
March 1, 2026
Ono Pharmaceutical : Announcement concerning the Transfer of Distribution, Sales and Termination of Co-promotion for SGLT2 Inhibitor “Forxiga® 5 mg, 10 mg Tablets’’ in Japan
February 27, 2026
Ono Pharmaceutical : Opdivo® (nivolumab) Intravenous Infusion Approved in South Korea in Combination with Yervoy® (ipilimumab) for the Treatment of Adult Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer
February 23, 2026
Ono Pharmaceutical : Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL
February 16, 2026
Ono Shares Replay Information for 44th Annual J.P. Morgan Healthcare Conference Presentation
January 15, 2026
Ono Pharmaceutical : Opdivo® Intravenous Infusion Approved in Taiwan in Combination with Yervoy® for the Treatment of Adult Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer
January 14, 2026
Ono to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
Scenic Biotech Enters License and Research Agreement with Ono Pharmaceutical
January 7, 2026
Ono Pharmaceutical : Receives Highest A-List Rating in CDP 2025 Report for Climate Change and Water Security Efforts
December 10, 2025
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting
December 6, 2025
Ono Pharmaceutical : Receives Supplemental Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer
November 20, 2025
PRISM BioLab Achieved Initial Milestone and Receives the Milestone Payment in Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd.
November 14, 2025
Ono Pharmaceutical : Updated Global Phase 1/2 Clinical Trial Data for Povetacicept, which was Granted Breakthrough Therapy Designation in IgA Nephropathy and Fast Track Designation in Primary Membranous Nephropathy from FDA
November 10, 2025
Ono Announces ONO-4578 in Combination with Opdivo and Chemotherapy Met the Primary Endpoint in a Phase 2 Clinical Trial in Patients with Certain Gastric Cancer
October 9, 2025
Ono Pharmaceutical : Announces -4578 (EP4 antagonist) in Combination with Opdivo and Chemotherapy Met the Primary Endpoint in a Phase 2 Clinical Trial in Patients with Certain Gastric Cancer
October 8, 2025
Ono Pharmaceutical : Announces Encouraging Efficacy Signals of -2808, a S1P5 Receptor Agonist, in an interim analysis of Ongoing Phase 2 Clinical Trial in Patients with Multiple System Atrophy
October 8, 2025
Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment
October 6, 2025
Ono Pharmaceutical : Submits an Application for Approval of Cenobamate (-2017), Antiseizure Medications in Japan
September 30, 2025
Deciphera Announces Positive CHMP Opinion for ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
July 28, 2025
Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea
June 23, 2025